Johnson & Johnson Executive VP Jennifer Taubert to Retire

What Happened
Johnson & Johnson announced (8-K filed Aug. 4, 2026) that Jennifer Taubert will retire from her role as Executive Vice President and Worldwide Chairman, Innovative Medicine, and as a member of the Executive Committee, effective September 1, 2026. The company attached a press release dated August 4, 2026 to the filing.

Key Details

• Filing date: August 4, 2026 (Form 8-K).
• Effective retirement date: September 1, 2026.
• Role affected: Executive Vice President, Worldwide Chairman, Innovative Medicine; member of the Executive Committee.
• Exhibit: Press release dated August 4, 2026 was included as Exhibit 99.1 to the 8-K.

Why It Matters
This is a senior leadership change at Johnson & Johnson in a major business area (Innovative Medicine). For investors, executive departures at the Executive Committee level are material corporate governance events — they can prompt updates on succession plans, organizational structure, or strategic priorities. Monitor J&J communications for announcements about Taubert’s successor or any related management transitions.